$1 Billion Oncology Alliance Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

27-Nov-2014 - Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announced that they have initiated the first-in-human clinical study of OBT357 (MEN1112), an enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five ...

Oxford BioTherapeutics Appoints Dr Eugen Leo as Head of Clinical Development

10-Jul-2014 - Oxford BioTherapeutics announced the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development. Dr. Leo brings substantial clinical development experience of targeted and first-in-class molecules, as well as extensive translational research experience, and will be responsible for ...

Menarini Group and Oxford BioTherapeutics sign Major Strategic Collaboration for the Clinical Development and Manufacture of a Portfolio of Novel Antibody-Based Cancer Drugs

31-Oct-2012 - Menarini and Oxford BioTherapeutics (OBT) announced a major strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer. The agreement covers five of OBT’s antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via ...

Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel

04-May-2012 - Oxford BioTherapeutics (OBT) announced the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this position he will lead the company’s newly created clinical development operations based in Basel, Switzerland. The establishment of a dedicated ...

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

Companies to combine proprietary technologies to generate novel ADC product candidates

15-Sep-2011 - Seattle Genetics, Inc. and Oxford BioTherapeutics (OBT) announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens ...

Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers

27-Jan-2011 - Oxford BioTherapeutics (OBT) announced that sanofi-aventis has acquired an exclusive world-wide license to one of OBT’s internal preclinical antibody programs.sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop, ...

Oxford BioTherapeutics Appoints Michael Moore as Chairman

10-Dec-2009 - Oxford BioTherapeutics (OBT) has announced the appointment of Dr Michael Moore as non-executive Chairman. Dr Moore has several decades of senior management experience in the biotechnology sector and joins the Board of OBT following five years at UK biotechnology company, Piramed Limited, where ...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

20-May-2009 - Oxford BioTherapeutics (OBT) announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer. Under the alliance, GSK will develop novel antibody therapies against ...

Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics

03-Dec-2008 - Oxford Genome Sciences announced that it has changed its name to Oxford BioTherapeutics (OBT). The new name will take effect immediately. According to the company, the name reflects the company’s complete focus on the discovery and development of targeted antibody medicines to address large and ...

Oxford Genome Sciences announces new Therapeutic Antibody Deal with Medarex

New agreement to drive the development of OGeS' own pipeline of antibodies in cancer

20-Sep-2007 - Oxford Genome Sciences (UK) Ltd (OGeS) announced a second partnering agreement with Medarex, Inc. This new agreement provides OGeS with broad access to Medarex's fully human antibody technology and will potentially enable OGeS to accelerate the development of its own pipeline of novel fully human ...